(redirected from Carboplatin)
Also found in: Medical, Encyclopedia, Wikipedia.
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Healthcare company Eli Lilly and Company (NYSE:LLY) reported on Tuesday the receipt of US Food and Drug Administration (FDA) approval for a new indication for ALIMTA in combination with carboplatin and KEYTRUDA for the treatment of nonsquamous non-small cell lung cancer (NSCLC).
Belinostat is administered as a 30-minute daily IV infusion on day one through five with carboplatin being administered on day three.
Tecentriq is also approved in combination with Avastin (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of adults with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
In an ongoing clinical trial, 786 women with ovarian cancer were randomized to receive paclitaxel plus carboplatin (399 patients) or paclitaxel plus cisplatin (387 patients).
Keytruda 200 mg and carboplatin AUC 6 mg/mL/min on Day 1 of each 21-day cycle for four cycles and paclitaxel 200 mg/m2 on Day 1 of each 21-day cycle for four cycles or nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 21-day cycle for four cycles, followed by Keytruda 200 mg every three weeks.
M2 EQUITYBITES-June 6, 2018-Eli Lilly and Company passes US FDA approval for new indication for ALIMTA, carboplatin and KEYTRUDA combination for NSCLC
6 January 2010 - Danish biotechnology firm TopoTarget A/S (CPH: TOPO) said today it started, via the US Gynecologic Oncology Group (GOG), a phase II trial with its candidate drug belinostat in combination with carboplatin, for the treatment of ovarian cancer.
Malignant pleural mesothelioma patients who received tumor treating fields with pemetrexed and cisplatin or carboplatin experienced median overall survival of 18.2 months compared to 12.1 months in a historical control.
Roche (SIX: RO, ROG; OTCQX: RHHBY) a Swiss multinational healthcare company, announced on Monday that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ(R) (atezolizumab), in combination with Avastin(R) (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC).
Pembrolizumab was previously granted accelerated approval for this indication in May 2017 based on improvements in overall response rate and progression-free survival for patients randomized to pembrolizumab administered with pemetrexed and carboplatin as compared with pemetrexed and carboplatin alone in the KEYNOTE-021 study.